Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the u...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://ncbi.nlm.nih.gov/pubmed/24192812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.330
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky